Compound muscle action potential of whole-forearm flexors: A clinical biomarker for inclusion body myositis

被引：0

作者：

Mano, Tomoo ^{[1
,2
]}

Iguchi, Naohiko ^{[1
]}

Iwasa, Naoki ^{[1
]}

Yamada, Nanami ^{[1
]}

Sugie, Kazuma ^{[1
]}

机构：

[1] Nara Med Univ, Dept Neurol, Kashihara, Japan

[2] Nara Prefecture Gen Med Ctr, Dept Rehabil Med, Nara, Japan

来源：

CLINICAL NEUROPHYSIOLOGY PRACTICE | 2024年 / 9卷

关键词：

Inclusion body myosis; Biomarker; Nerve -conduction study; Forearm flexor muscle; Compound muscle action potential; NEUROPATHY; BIMAGRUMAB; SEVERITY; EFFICACY; SAFETY;

D O I：

10.1016/j.cnp.2024.03.003

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Objective: This study aimed to investigate the potential of whole -forearm flexor muscle (WFFM) compound muscle action potential (CMAP) as a quantitative biomarker for inclusion body myositis (IBM) pathology. Methods: We prospectively enrolled 14 consecutive patients (10 men and 4 women) diagnosed with IBM based on muscle biopsies. We evaluated the baseline -to -peak amplitude of the WFFM CMAP and other quantitative parameters, including grip and pinch strength, Inclusion Body Myositis Functional Rating Scale (IBMFRS) score, and other routine muscle CMAP amplitudes. Results: The WFFM CMAP was strongly correlated with disease duration and the IBMFRS score. The WFFM CMAP on the more affected side was lower than that on the less affected side. Furthermore, grip power was strongly correlated with the WFFM CMAP, whereas lateral pinch strength was strongly correlated with the WFFM and first dorsal interosseous CMAPs. The 3 -point pinch strength was also correlated with the WFFM CMAP. Conclusions: This study demonstrates that the WFFM CMAP may serve as a biomarker of severity in IBM. Significance: Identification of this biomarker can support drug development, diagnosis, prognosis, and treatment options for patients with IBM. (c) 2024 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页码：162 / 167

页数：6

共 28 条

[1] Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis Long-term Extension of RESILIENT [J].

Amato, Anthony A. ;

Hanna, Michael G. ;

Machado, Pedro M. ;

Badrising, Umesh A. ;

Chinoy, Hector ;

Benveniste, Olivier ;

Karanam, Ananda Krishna ;

Wu, Min ;

Tanko, Laszlo B. ;

Schubert-Tennigkeit, Agnes Annette ;

Papanicolaou, Dimitris A. ;

Lloyd, Thomas E. ;

Needham, Merrilee ;

Liang, Christina ;

Reardon, Katrina A. ;

de Visser, Marianne ;

Ascherman, Dana P. ;

Barohn, Richard J. ;

Dimachkie, Mazen M. ;

Miller, James A. L. ;

Kissel, John T. ;

Oskarsson, Bjorn ;

Joyce, Nanette C. ;

Van den Bergh, Peter ;

Baets, Jonathan ;

De Bleecker, Jan L. ;

Karam, Chafic ;

David, William S. ;

Mirabella, Massimiliano ;

Nations, Sharon P. ;

Jung, Hans H. ;

Pegoraro, Elena ;

Maggi, Lorenzo ;

Rodolico, Carmelo ;

Filosto, Massimiliano ;

Shaibani, Aziz, I ;

Sivakumar, Kumaraswamy ;

Goyal, Namita A. ;

Mori-Yoshimura, Madoka ;

Yamashita, Satoshi ;

Suzuki, Naoki ;

Aoki, Masashi ;

Katsuno, Masahisa ;

Morihata, Hirokazu ;

Murata, Kenya ;

Nodera, Hiroyuki ;

Nishino, Ichizo ;

Romano, Carla D. ;

Williams, Valerie S. L. ;

Vissing, John .

NEUROLOGY, 2021, 96 (12) :E1595-E1607

[2]

Aoki Masashi, 2014, Rinsho Shinkeigaku, V54, P1115, DOI 10.5692/clinicalneurol.54.1115

[3] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].

CHARLSON, ME ;

POMPEI, P ;

ALES, KL ;

MACKENZIE, CR .

JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383

[4] Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis [J].

Cox, Fieke M. ;

Reijnierse, Monique ;

van Rijswijk, Carla S. P. ;

Wintzen, Axel R. ;

Verschuuren, Jan J. ;

Badrising, Umesh A. .

RHEUMATOLOGY, 2011, 50 (06) :1153-1161

[5] Inclusion Body Myositis [J].

Dimachkie, Mazen M. ;

Barohn, Richard J. .

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2013, 13 (01)

[6]

FELSENTHAL G, 1986, ARCH PHYS MED REHAB, V67, P440

[7] Correlations of disease severity outcome measures in inclusion body myositis [J].

Goyal, Namita A. ;

Greenberg, Steven A. ;

Cauchi, Jonathan ;

Araujo, Nadia ;

Li, Vivian ;

Wencel, Marie ;

Irani, Tyler ;

Wang, Leo H. ;

Palma, Anton M. ;

Villalta, S. Armando ;

Mozaffar, Tahseen .

NEUROMUSCULAR DISORDERS, 2022, 32 (10) :800-805

[8] Quantitative MRI Biomarkers as Potential Inclusion Body Myositis Clinical Trial Endpoints [J].

Greenberg, Steven A. ;

Dmitrienko, Alex ;

Hayes, Mark .

NEUROLOGY, 2022, 99 (09) :361-362

[9] INCLUSION-BODY MYOSITIS AND MYOPATHIES [J].

GRIGGS, RC ;

ASKANAS, V ;

DIMAURO, S ;

ENGEL, A ;

KARPATI, G ;

MENDELL, JR ;

ROWLAND, LP .

ANNALS OF NEUROLOGY, 1995, 38 (05) :705-713

[10] Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial [J].

Hanna, Michael G. ;

Badrising, Umesh A. ;

Benveniste, Olivier ;

Lloyd, Thomas E. ;

Needham, Merrilee ;

Chinoy, Hector ;

Aoki, Masashi ;

Machado, Pedro M. ;

Liang, Christina ;

Reardon, Katrina A. ;

de Visser, Marianne ;

Ascherman, Dana P. ;

Barohn, Richard J. ;

Dimachkie, Mazen M. ;

Miller, James A. L. ;

Kissel, John T. ;

Oskarsson, Bjoern ;

Joyce, Nanette C. ;

Van den Bergh, Peter ;

Baets, Jonathan ;

De Bleecker, Jan L. ;

Karam, Chafic ;

David, William S. ;

Mirabella, Massimiliano ;

Nations, Sharon P. ;

Jung, Hans H. ;

Pegoraro, Elena ;

Maggi, Lorenzo ;

Rodolico, Carmelo ;

Filosto, Massimiliano ;

Shaibani, Aziz, I ;

Sivakumar, Kumaraswamy ;

Goyal, Namita A. ;

Mori-Yoshimura, Madoka ;

Yamashita, Satoshi ;

Suzuki, Naoki ;

Katsuno, Masahisa ;

Murata, Kenya ;

Nodera, Hiroyuki ;

Romano, Carla D. ;

Williams, Valerie S. L. ;

Vissing, John ;

Auberson, Lixin Zhang ;

Wu, Min ;

de Vera, Ana ;

Papanicolaou, Dimitris A. ;

Amato, Anthony A. ;

Nishino, Ichizo .

LANCET NEUROLOGY, 2019, 18 (09) :834-844

← 1 2 3 →